Meta-analysis on the effect of hyperbaric oxygen as adjunctive therapy in the outcome of anastomotic healing of experimental colorectal resections in rats

Robin J Brouwer¹, Alexander C Engberts¹, Boudewijn LS Borger van der Burg¹, Thijs TCF van Dongen^{1,2}, Rob A van Hulst^{3,4}, Rigo Hoencamp^{1,2,5}

¹ Department of Surgery, Alrijne Hospital, Leiderdorp, The Netherlands

²Defense Healthcare Organization, Ministry of Defense, Utrecht, The Netherlands

³ Department of Anesthesiology, Amsterdam Medical Center, Amsterdam, The Netherlands

⁴ Maritime Medical Expertise Center, Diving Medical Center, Royal Netherlands Navy, Den Helder, The Netherlands

⁵ Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

Corresponding author: RJ Brouwer, Department of Surgery, Alrijne Hospital, Simon Smitweg 1, 2353 GA Leiderdorp, The Netherlands

<u>rjbrouwer@alrijne.nl</u>

Key words

Surgery; Gastrointestinal tract; Animal model; Hyperbaric research; Systematic review

Abstract

(Brouwer RJ, Engberts AC, Borger van der Burg BLS, van Dongen TTCF, van Hulst RA, Hoencamp R. Meta-analysis on the effect of hyperbaric oxygen as adjunctive therapy in the outcome of anastomotic healing of experimental colorectal resections in rats. Diving and Hyperbaric Medicine. 2018 September;48:173–185. <u>doi: 10.28920/dhm48.3.173-185</u>. <u>PMID: 30199890</u>.)

Background: Colorectal cancer is the third most common form of cancer and colorectal surgery is the treatment of choice in local disease. Anastomotic leakage following colorectal surgery is a major complication with a high incidence and mortality. Adjuvant hyperbaric oxygen treatment (HBOT) may be associated with reduction of anastomotic leakage. A systematic review was conducted regarding HBOT as an adjunctive therapy to colorectal surgery.

Methods: Systematic review (1900–2017) using PubMed, Cochrane, EMBASE, Web of Science and EMCARE. All original published studies on the effect of HBOT as an adjunctive therapy for colorectal surgery with the creation of an anastomosis were considered.

Results: Thirteen small animal trials were included for qualitative synthesis. We found no human trials. Eleven trials used bursting pressure whilst eight used hydroxyproline levels as a marker for collagen synthesis as primary outcome to assess the strength of the anastomosis. A meta-analysis performed for normal and ischaemic anastomoses showed that postoperative HBOT improves bursting pressure and hydroxyproline levels significantly in both normal ($P \le 0.001$ and P = 0.02 respectively) and ischaemic anastomoses ($P \le 0.001$ and P = 0.04 respectively).

Conclusion: Postoperative HBOT has a positive effect on colorectal anastomoses in rats. Further research should focus on a larger systematic animal study.

Introduction

Colorectal cancer is the third most common form of cancer with an incidence of almost 1.4 million cases in 2012 according to the WHO.¹ Colorectal surgery is the treatment of choice in local carcinoma.^{2,3} A major complication following colorectal surgery is anastomotic leakage (AL) with a reported incidence of 10–13% and a mortality of up to 33%.⁴ A recent meta-analysis showed that AL is associated with local recurrence and reduced survival.⁵ Hyperbaric oxygen treatment (HBOT) has been suggested as adjunct therapy to reduce the risk of AL.

HBOT involves breathing 100 percent oxygen at two to three times normal atmospheric pressure and results in elevated oxygen tension in arteries and tissue.⁶ HBOT is already

being used widely as a treatment for a variety of indications as set out in published recommendations of the Undersea and Hyperbaric Medical Society and the European College of Hyperbaric Medicine.^{7,8} HBOT has a variety of mechanisms of action: it improves tissue oxygenation; inhibits the proinflammatory reaction by reducing cytokines; improves neo-vascularization; has a bacteriostatic effect on anaerobic bacteria and stimulates stem cells and growth factors.⁹ HBOT is considered a low-risk therapy. Described side effects are middle ear barotrauma (up to 43%, usually mild), myopia, aerosinusitis, (acute and chronic) oxygen poisoning including seizures and lung failure.^{10,11}

Preconditioning with HBOT might be useful as an adjunct for various types of surgery. For instance, a better outcome in left ventricular function was demonstrated




Figure 1 PRISMA flow chart for meta-analysis

after on-pump coronary artery bypass surgery after pretreatment with three HBOT sessions,¹⁰ whilst in patients undergoing pancreaticoduodenectomy, a single preoperative HBOT appeared to improve outcome.¹² Furthermore, preconditioning with HBOT is associated with a reduction in the interleukin inflammatory markers IL-6 and IL-10.¹²

The effect of HBOT on cancer depends highly on the type of cancer; it might even have an inhibitory effect on certain types of cancer.¹³ The current consensus is that there is no scientific evidence that HBOT has a cancer-promoting effect.^{13,14} including in colorectal cancer.¹⁵ The latter study concluded that HBOT does not promote the growth or recurrence of colorectal cancer, but that treating colorectal cancer solely with HBOT does not seem to have a beneficial effect.

Although strong evidence is still lacking, HBOT could potentially be an adjunct in the treatment of colorectal cancer. The primary aim of this systematic review and metaanalysis is to provide the best evidence to date regarding the effects of HBOT as an adjunctive therapy on anastomotic healing after colorectal surgery.

Methods

The protocol for objectives, literature search strategies, inclusion and exclusion criteria, outcome measurements, and methods of statistical analysis was prepared *a priori*, according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement,^{16,17} and is described in this section.

LITERATURE SEARCH STRATEGY

A systematic review (1900–2017) was performed in PubMed, Cochrane, EMBASE, Web of Science and EMCARE. The keywords used in the search were "hyperbaric oxygenation" and its synonyms in combination with "colorectal surgery", "colectomy" and their equivalents. Also, the combination of "surgery" and its synonyms, with "colon", "rectum", "sigmoid" and their equivalents was used. The search was limited to original studies published in English.

Inclusion and exclusion criteria, data extraction and outcomes of interest

Two authors (RJB, ACE) independently identified the studies for inclusion and exclusion and extracted the data. The accuracy of the extracted data was further confirmed by a third author (RH). Studies were included when they used colorectal surgery, including the formation of an anastomosis, in combination with HBOT.

QUALITY ASSESSMENT

The quality of trials was assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk-of-bias tool.¹⁷ This tool is designed to assess bias in animal studies and contains ten items to investigate bias in selection, performance, detection, attrition and reporting. Ten points are scored for every item complied with. No points are awarded when the study does not meet the criterium or when documentation is unclear. The total score ranges from 0 to 100 with 0 being the worst, with a high chance of bias, and 100 being the best score, seemingly free from bias.

OUTCOME MEASURES

The main outcome measures of the included studies were bursting pressure (BPR) and hydroxyproline levels (HP). BPR involves a measurement whereby air is instilled in a closed segment of bowel with the anastomosis, and established by means of a sudden decline in pressure or visualization of air bubbles in a submerged anastomosis. Hydroxyproline is formed during the synthesis of collagen and has proven to be a good predictor for AL.¹⁸ Other outcomes measured in some studies were histopathological analysis (HA), various biochemical analyses and the total energy of rupture biomechanical test (ETR).

STATISTICAL ANALYSIS

The software package Review Manager 5.3,¹⁹ was used to perform a meta-analysis of the primary outcome sources, which was determined after careful study of the results. An

inversed variance test was used for the meta-analysis. In all cases, P < 0.05 (two-sided) was considered statistically significant.

Results

The PRISMA literature search and study selection are shown in Figure 1. Thirteen animal trials were included for qualitative and quantitative synthesis (Table 1).^{4,20–31}, Appendix A* identifies where each item in the PRISMA checklist may be found in this report. In addition, Appendix B* presents the full electronic search strategy such that it could be repeated.

STUDY PROTOCOLS

All animal trials reported the effect of HBOT on colonic anastomoses in rats (Table 1). Ten studies^{20–22,24–29,31} used postoperative HBOT, one study used a combination of preand postoperative (combined) HBOT,⁴ one had two study groups researching postoperative and combined HBOT³⁰ and the last study had three study groups analyzing preoperative, postoperative and combined HBOT.²³ All studies performed open surgery with one exception which used a laparoscopic technique.³⁰ There is wide variation in the HBOT protocols in terms of the treatment intervals, durations of treatment, length of the HBOT courses and pressures.

QUALITY ASSESSMENT

The quality assessment using the SYRCLE tool is shown in Table 2. None of the studies met all quality criteria. Six studies^{4,24,26,29–31} randomized the study and control groups, but none of the studies provided baseline statistics, potentially concealing selection bias. None of the studies randomly selected the animals for outcome assessment or described blinding the outcome assessor. In only one study were the investigators blinded.³⁰ In all but one²³ of the seven studies that included pathologic analysis,^{4,23,24,27–29,31} the outcome assessor for the analysis was blinded, decreasing the chance of detection bias. Overall, the included studies generally lacked steps in their protocols to minimize the chance of (any kind of) bias.

NON-ISCHAEMIC ANASTOMOSIS

Ten^{4,20,21,23,25,27–31} of the thirteen studies focused on nonischaemic anastomosis in normal conditions (Table 3). One study used three study groups – preoperative, postoperative and combined HBOT,²² whilst another used two study groups – postoperative and combined HBOT,²⁹ resulting in a total of thirteen different study groups. Of these thirteen study groups, five study groups from five different studies reported a significant improvement of the anastomosis after HBOT

* Footnote: Follow this link to <u>Appendices A and B.</u> Alternatively these files may be obtained from the corresponding author at: <u>rjbrouwer@alrijne.nl</u>

Study protocol of included animal trials; HBOT – hyperbaric oxygen therapy; M – male; F – female; d – days; ATA – atmosphere absolute; CRT – chemoradiotherapy; CT – Chemotherapy; GH – growth hormone; BPR – bursting pressure; HP – hydroxyproline; PPg-glucan – poly B1-6 glucotriosys B1-3 glucopyranose glucan; PA – pathological analysis; MMP – matrix-metalloproteinase; BA – biochemical analysis; ETR – total energy of rupture biomechanical test

Author	u	Species/ sex	Intervention	Pre/postop HBOT	HBOT days / length (min) / pressure (kPa)	Additional interventions	Measured outcomes
Boersema ⁴	10	Wistar, M	Colectomy	Pre- and postop	7 preop + 3 postop / 1 x 90 / 243	None	BPR+PA
Hamzaoğlu ²⁰	10	Wistar, M	Left colon resection	Postoperative	4 / 1 x 60 / 253	Induced ischaemia	BPR+HP
Erenoglu ²¹	10	Wistar, M	Colectomy	Postoperative	7 / 2 x 90 / 203	Preoperative CRT	BPR+HP
Guzel ²²	10	Wistar, F	Induced ischaemia + colonic anastomosis	Postoperative	4 / 1 x 60 / 253	PPg-glucan	BPR+HP
Yagci ²³	10	Wistar, M	Left colon resection	Preoperative	2 / 2 x 90 / 284	Induced ischaemia	BPR+HP+PA
Yagci ²³	10	Wistar, M	Left colon resection	Postoperative	4 / 2 x 90 / 284	Induced ischaemia	BPR+HP+PA
Yagci ²³	10	Wistar, M	Left colon resection	Pre- and postop	2 preop + 4 postop / 2 x 90 / 284	Induced ischaemia	BPR+HP+PA
Sucullu ²⁴	∞	Wistar, M/F	Induced peritonitis + colectomy	Postoperative	3 or 7 / 1 x 90 / 253	None	BPR+HP+PA
Azevedo ²⁵	10	Wistar, ?	Colectomy	Postoperative	7 / 1 x 90 / 203	Induced ischaemia	HP+MMP1+MMP9
Rocha ²⁶	15	Wistar, F	Induced peritonitis + colectomy	Postoperative	4 / 1 x 120 / 203	None	ETR
Adas ²⁷	10	Wistar, M	Left colon resection	Postoperative	4 / 3 x 60 / 253	GH	BPR+PA
Kemik ²⁸	10	Wistar, F	Left colon resection	Postoperative	4 / 4 x 80 / 253	CT	BPR+PA
Yildiz ²⁹	12	Wistar, F	Left colon resection	Postoperative	5/2 x 90/ unknown	Preoperative CRT	BPR+HP+PA
Poyrazoglu ³⁰	7	Sprague- Dawley, M	Left colon resection	Postoperative	4 / 1 x 120 / 284	None	BPR+BA
Poyrazoglu ³⁰	٢	Sprague- Dawley, M	Left colon resection	Pre- and postop	2 h preop + 4 postop / 1 x 120 / 284	None	BPR+BA
Emir ³¹	10	Wistar, M	Laparoscopic left colon resection	Postoperative	10 / 1 x 60 / 213	None	BPR+HP+PA

Quality assessment using the SYRCLE risk of bias tool; 1 = yes, 2 = no, 3 = unclear; 10 points are scored for every item complied with and no points are awarded when the study does not meet the criterium or when documentation is unclear; total score ranges from 0–100, 0 being the worst, with a high chance of bias, and 100 being the best score, seemingly free from bias

Author					S	SYRC	LE to	ool ¹⁷ q	uesti	on nu	mber			
	1	2	3	4	5	6	7	8	9	10	Yes	Unclear	No	Score
Hamzaoglu ²⁰	3	3	3	2	3	3	3	1	1	2	2	2	6	20
Erenoglu ²¹	3	3	3	2	3	3	3	1	1	2	2	2	6	20
Guzel ²²	2	3	2	1	2	3	3	1	1	2	3	4	3	30
Yagci ²³	3	3	3	1	3	3	3	1	1	2	3	1	6	30
Sucullu ²⁴	1	3	3	1	3	3	3	1	1	2	5	1	4	50
Azevedo ²⁵	3	3	3	1	3	3	3	1	3	2	2	1	7	20
Rocha ²⁶	1	3	3	1	3	3	3	1	3	2	3	1	6	30
Adas ²⁷	3	3	3	1	3	3	3	1	1	2	3	1	6	30
Kemik ²⁸	3	3	3	1	3	3	3	1	1	1	4	0	6	40
Yildiz ²⁹	1	3	3	1	3	3	3	1	1	2	4	1	5	40
Poyrazoglu ³⁰	1	3	3	2	3	3	3	1	1	2	3	2	5	30
Boersema ⁴	1	3	3	2	3	3	3	1	1	1	4	1	5	40
Emir ³¹	1	3	1	1	1	3	3	1	1	2	6	1	3	60

treatment.^{4,20,25,27,30} In the other eight study groups, analyzed by six different studies, any observed improvement of the anastomosis did not reach statistical significance.^{21,23,28–31} There was no association between HBOT and anastomosis strength in the study groups assessing preoperative or combined HBOT.^{4,23,30}

The BPR was measured in twelve study groups, from nine different studies, and was higher in the HBOT group in all study populations.^{4,20,21,23,27–31} A significant increase of BPR was observed in three study groups, analysed by three different studies.^{20,27,30} HP was measured in ten study groups from seven different studies.^{20,21,23,25,29–31} Of these ten study groups, HP was significantly higher in seven study groups, analysed by five different studies.^{20,21,23,25,29–31} Of these ten study groups, the was significantly higher in seven study groups, analysed by five different studies.^{20,21,23,25,30} There was a marked variation in HP levels (Table 3). Six studies^{20–22,25,30,31} measured HP in grams in tissue, while two studies^{23,29} measured HP molarity in tissue. One study²² measured HP in wet tissue, whilst another³¹ dried the tissue for 24 hours before analysis. The remaining six studies^{20,21,23,25,29,30} measuring HP did not describe how they prepared the tissue for analysis.

HISTOPATHOLOGICAL ANALYSIS

The histopathological analysis varied between studies. Three studies assessed anastomotic line fibrosis and found no significant difference between any groups.^{23,24,29} Another assessed the formation of a mucosal layer and the severity of inflammation at the anastomosis and found no significant differences.³⁰ Three studies found a significant increase in neovascularization in the HBOT group.^{4,27,28} The same three studies assessed collagen deposition, but only one found a significant increase in collagen deposition in the HBOT group.²⁶ No significant differences were found in necrosis, epithelialization or granulation.^{26,27} All tissue biochemical markers changed in the study group that received only postoperative HBOT.²⁹ Malondialdehyde (MDA), an indicator of fat oxidation, and myeloperoxidase, an indicator of inflammation, were lowered and superoxide dismutase and glutathione peroxidase, both indicators of the antioxidant response, were elevated.²⁹ In the study group that received both pre- and postoperative HBOT, only MDA was significantly lower.²⁹ In another study measuring nitric oxide, MDA and catalase in serum and tissue, a significant decrease was demonstrated only in serum MDA in the HBOT group.30

ISCHAEMIC ANASTOMOSES

Seven study groups from five different studies assessed the influence of HBOT on ischaemic anastomoses (Table 4).^{20,22,23,25,27} In six groups from the five studies, HBOT had a positive effect on the anastomosis. The only exception was

Outcome of studies assessing normal anastomoses; HBOT – hyperbaric oxygen treatment; Prob. – probability; ALF – anastomotic line fibrosis; U – unknown; MMP – matrix-metalloproteinase; ns - not significant; \uparrow - significantly increased; \downarrow - significantly decreased; NV - neovascularization; CD - collagen deposition; N - necrosis; E - epithelialization; G - granulation; FML - formation of mucosal layer; SI – severity of inflammation; tMDA – tissue malondialdehyde; tMPO – tissue myeloperoxidase; tSOD – tissue superoxide dismutase; tGSH-Px – tissue glutathionperoxidase; sMDA – serum malondialdehyde; sNO – serum nitric oxide; sCAT – serum catalase; tNO – tissue nitric oxide; tCAT – tissue catalase

Author	Burstin	Bursting pressure (mmHg)	iHg)		Hydrox	Hydroxyproline		Pathology	Other	Improved
	HBOT	Control	P ≤ 0.05	HBOT	Control	Units	P < 0.05			
Hamzaoğlu ²⁰	123 ± 18.4	104 ± 18.9	Yes	10.12 ± 4	7.4 ± 2	mg·mg tissue ⁻¹	Yes	I	1	Yes
Erenoglu ²¹	221 ± 6.05	190.2 ± 18.14	No	22.88 ± 2.38	9.01 ± 2.04	µg·10 mg tissue ⁻¹	Yes	I	1	No
Yagci ²³	115.5 ± 21.1	107.2 ± 37.5	No	13.89 ± 3.43	9.95 ± 2.65	μM·mg tissue ⁻¹	Yes	ALF ns	I	No
Yagci ²³	113.6 ± 16.9	107.2 ± 37.5	No	13.11 ± 4.39	9.95 ± 2.65	µM·mg tissue ⁻¹	Yes	ALF ns	I	No
Yagci ²³	119.2 ± 16.7	107.2 ± 37.5	No	13.25 ± 3.27	9.95 ± 2.65	µM·mg tissue ⁻¹	Yes	ALF ns	I	No
Azevedo ²⁵	I	I	I	Unknown	Unknown	µg·mg tissue ⁻¹	Yes	I	MMP1 ns; MMP9 ns	Yes
$Adas^{27}$	93.3 ± 20.5	81.4 ± 20.1	Yes	I	I	I	I	CD↑; NV↑; N ns; E ns; G ns	I	Yes
Kemik ²⁸	93.4 ± 24.8	84.5 ± 24.4	No	I	I	I	I	NV↑; CD ns; N ns; E ns; G ns	I	No
Yildiz ²⁹	133.7 ± 29.7	110.7±18.6	No	17.3 ± 6.6	15 ± 5.8	µM·mg ⁻¹ tissue ⁻¹	No	ALF ns	I	No
Poyrazoglu ³⁰	152.9 ± 18	122.6 ± 16.7	Yes	83 ± 11.1	60.4 ± 14.4	mg·g protein ⁻¹	Yes	I	tMDA↓; tMPO↓; tSOD↑; tGSH-Px↑	Yes
Poyrazoglu ³⁰	126 ± 13.6	122.6 ± 16.7	No	63.7 ± 18.7	60.4 ± 14.4	mg.g protein ⁻¹	No	I	tMPO↓; tMDA ns; tSOD ns; tGSH-Px ns	No
Boersema ⁴	162.4 ± 39.7	141.1 ± 73.3	No	I	I	I	I	NV↑; CD206+↑; M2/M1↑; CD ns; iNOS+ ns	I	Yes
Emir ³¹	213 ± 27	197 ± 9.1	No	26.5 ± 4.1	26.8 ± 4.36	μg·10 mg tissue ⁻¹ (dry)	No	FML ns; SI ns	sMDA↓; sNO ns; CAT ns; tMDA ns; tNO ns; tCAT ns	No

Outcome of studies assessing ischemic anastomoses; HBOT- hyperbaric oxygen treatment; ALF- anastomotic line fibrosis; ns - not significant; MMP - matrix-metalloproteinase; granulation enithelialization. G -Ľ necrosis. neovascularization: N collagen denosition NV sionificantly decreased. CD significantly increased.

Author	Bursting	Bursting pressure (mmHg)	Hg)		Hyd	Hydroxyproline		Pathology	Other]	Improved
	HBOT	Control	Prob. < 0.05	HBOT	Control	Units	Prob. ≤ 0.05			
Hamzaoğlu ²⁰	102.2 ± 14.8 77.5 ± 22.1	77.5 ± 22.1	Yes	6.04 ± 2	4.76 ± 2	mg·mg tissue ⁻¹	Yes	I		Yes
Guzel ²²	104 ± 19.4	69.5 ± 16.7	Yes	12.1 ± 1.1	4.3 ± 0.6	mg·100 mg wet tissue ⁻¹	Yes	I		Yes
Yagci ²³	81.2 ± 9.2	79.3 ± 7.7	No	9.51 ±. 87	8.42 ± 2.1	µM·mg tissue ⁻¹	No	ALF ns		No
Yagci ²³	97.9 ± 17.9	79.3 ± 7.7	Yes	10.01 ± 1.88	8.42 ± 2.1	µM·mg tissue ⁻¹	No	ALF ns		Yes
Yagci ²³	109.0 ± 8.4	79.3 ± 7.7	Yes	11.06 ± 1.95	8.42 ± 2.1	μM·mg tissue ⁻¹	Yes	ALF ns		Yes
Azevedo ²⁵	I	I	I	Unknown	Unknown	µg·100mg tissue ⁻¹	No	I	MMP1↑; MMP9↑	Yes
Adas ²⁷	109.9 ± 25.3 62 ± 21.19	62 ± 21.19	Yes	I	I	I	I	CD↑; NV↑; N↓; E ns; G ns		Yes

the group that received preoperative HBOT only.²³ Five study groups analyzed by four studies, found a significant improvement in the BPR.^{20,22,23,27} Three study groups from three of these studies, also found a significant improvement in HP.^{20,22,23}

ANASTOMOSES DURING PERITONITIS

Two studies^{24,26} investigated the effect of HBOT on colonic anastomoses created during peritonitis. One²⁴ observed an improvement in the anastomosis during peritonitis with a significantly higher BPR, but this observation using ETR as outcome measure was not supported by the other.²⁵

META-ANALYSIS

Meta-analyses on the studies using BPR and HP as outcome measures were performed and included the studies assessing normal and ischaemic anastomoses.^{4,20–23,25,27–31} The results are displayed as Forest plots in Figures 2 through 5. Only one study analyzed the effect of preoperative HBOT on both normal and ischaemic anastomoses, and the effect of combined HBOT on ischaemic anastomoses.23 Therefore, this meta-analysis will not provide extra insights for these groups. For the BPR group, the mean difference (MD) is displayed. Because of the variety in the test determining HP, a standardized mean difference (SMD) was used and because of the high variance of the HBOT protocols between the studies, a random effect was chosen for this meta-analysis. For meta-analysis including the studies using BPR to assess normal anastomoses, a low statistical heterogeneity was found ($I_2 = 12\%$). The other three meta-analyses showed high statistical heterogeneity ($I_2 = 74\%$, 88% and 84% respectively) and, therefore, should be interpreted with caution.

The BPR and HP in the postoperative group of normal anastomoses are significantly improved as shown in Figure 2 and 3 (MD = 20.8 mmHg (14.4, 27.3), $P \le 0.001$; SMD = 1.2 (0.20, 2.23), P = 0.02). The BPR and HP of the studies performing combined HBOT do not show a significant improvement (MD = 6.8 mmHg (-6.3, 19.9), P = 0.31, SMD = 0.7 (-0.20, 1.51), P = 0.14). The postoperative group of ischaemic anastomoses (Figures 4 and 5) show significant improvement in both BPR and HP (MD = 29.8 mmHg (17.9, 41.7), $P \le 0.001$, SMD = 2.6 (0.11, 5.13), P = 0.04).

Forest plot showing the effect of HBOT on bursting pressure (BPR) in normal anastomoses; HBOT – hyperbaric oxygen treatment; SD – standard deviation; IV – inverse variance, Random – random effect, CI – confidence interval; preop – preoperative; Z – Z-test; P – probability; postop – postoperative; Chi2 – chi-square test; I2 – I-square test for heterogeneity; df - degrees of freedom Figure 2

Mean difference	IV, Random, [95% CL]			1 ⁷			ł			•		ł	ŀ	•					ł					•	
Mear	IV, Rano		17					J.											1						
ence	6 CL] Year		37] 2006 7]			35] 1998	55] 2003	39] 2006	l6] 2013	33] 2013	39] 2013	l9] 2015	36J 2016	5]				14] 2006	35] 2015	<u>37</u>] 2016	0]			5]	
Mean difference	IV, Random, [95% CL] Year		8.30 [-18.37, 34.97] 8.30 [-18.37, 34.97]			19.00 [2.65, 35.35]	30.80 [18.95, 42.65]	6.40 [-19.09, 31.89]	8.90 [-12.66, 30.46]	23.00 [3.17, 42.83]	11.90 [-5.89, 29.69]	30.30 [12.11, 48.49]	16.00 [-1.66, 33.66]	20.84 [14.42, 27.25]				12.00 [-13.44, 37.44]	3.40 [-12.55, 19.35]	21.30 [-30.37, 72.97]	6.82 [-6.26, 19.90]			100.0% 17.65 [11.75, 23.55]	
	Weight		4.6% 4.6%			11.0%	18.5%	5.0%	6.8%	7.9%	9.5%	9.2%	9.7%	77.6%				5.0%	11.5%		17.8%			100.0%	
Control	SD Total Weight		10 10			10	10	10	10	12	10	7	10	79	^ 0			10	7		27	, 0		116	
ŏ	SD		37.5			18.9	18.14	37.5		18.6	20.1	16.7	9.1		0.38); I² = 7%				16.7	73.3		0.73); l² = 0%			
	Mean		107.2			104	190.2	107.2	84.5	110.7	81.4	122.6	197					107.2	122.6	141.1		= 0.73)			
	Total		1 0			10	10	10	10	12	10	7	10	79	= 7 (P	(1		10	7	1 9	27	= 2 (P		116	
HBOT	SD		115.5 21.1	0.54)		18.4	6.05	16.9	24.8	29.7	20.5	18	27		.51, df	0.0000		119.2 16.7	126 13.6	39.7		.64, df	(
_	Mean		115.5	e 31 (P =		123	221	113.6	93.4	133.7	93.3	152.9	213		Chi ² = 7	36 (P <	e HBOT	119.2	126	162.4		$Chi^2 = 0$			
	Study or Subgroup	1.1.1 Preoperative HBOT	Yagci (preop) ²³ Subtotal [95% CL]	Heterogeneity: Not applicable Test for overall effect: Z = 0.61 (P = 0.54)	1.1.2 Postoperative HBOT	Hamzaoğlu ²⁰	Erenoglu ²¹	Yagci (postop) ²³	Kemik ²⁸	Yildiz ²⁹	Adas ²⁷	Poyrazoglu (postop) ³⁰	Emir ³¹	Subtotal [95% CL]	Heterogeneity: Tau ² = 5.91; Chi ² = 7.51, df = 7 (P =	Test for overall effect: $Z = 6.36$ (P < 0.00001)	1.1.3 Pre and postoperative HBOT	Yagci (pre+postop) ²³	Poyrazoglu (pre+postop) ³⁰	Boersema ⁴	Subtotal [95% CL]	Heterogeneity: Tau ² = 0.00; Chi ² = 0.64, df = 2 (P = Tast for overall effect: $7 = 1.02$ (P = 0.31)		Total [95% CL]	

	HBOT	F	0	Control			Std. mean difference	Std. mean difference
Study or Subgroup	Mean SD Total Mean	D Total	Mean	SD 1	Total	Total Weight	IV, Random, [95% CL] Year	IV, Random, [95% CL]
1.2.1 Preoperative HBOT								
Yagci (preop) ²³ Subtotal [95% CL]	13.89 3.43	10 10	9.95	2.65	6 6	11.8% 11.8%	1.23 [0.26, 2.21] 2006 1.23 [0.26, 2.21]	₩
Heterogeneity: Not applicable	e						1	,
Test for overall effect: $Z = 2.48$ (P = 0.01)	.48 (P = 0.0 ⁻	.						
1.2.2 Postoperative HBOT								
Hamzaoğlu ²⁰	10.12	4 10	7.4	7	10	12.1%	0.82 [-0.10, 1.75] 1998	
Erenoglu ²¹	22.876 2.3	3 10	9.009	2.043	10	5.6%	6.11 [3.82, 8.39] 2003	
Yagci (postop) ²³	13.11 4.39	10 10	9.95	2.65	10	12.1%	0.83 [-0.09, 1.76] 2006	ŀ
Yildiz ²⁹	17.3 6.6	6 12	15	15.8	12	12.8%	0.18 [-0.62, 0.99] 2013	+
Poyrazoglu (postop) ³⁰	83 11.1	1 7	60.4	14.4	7	10.0%	1.65 [0.37, 2.92] 2015	•
Emir ³¹	26.5 4.1	1 10	26.8	4.36	10	12.4%	-0.07 [-0.94, 0.81] 2016	₽
Subtotal [95% CL]		59			59	65.0%	1.22 [0.20, 2.23]	
Heterogeneity: Tau ² = 1.26; Chi ² = 28.28, df = 5 (P <	$Chi^2 = 28.28$	3, df = 5 (P < 0.00	0.0001); l ² = 82%	82%			
Test for overall effect: Z = 2.34 (P = 0.02)	.34 (P = 0.0	2)						
1.2.3 Pre and postoperative HBOT	e HBOT							
Yagci (pre+postop) ²³	13.25 3.27	7 10	9.95	2.65	10	11.9%	1.06 [0.11, 2.01] 2006	+
Poyrazoglu (pre+postop) ³⁰	63.7 18.7	7 7	60.4	14.4	~ ;	11.3%	0.19 [-0.87, 1.24] 2015	ŀ
Subtotal [95% CL]		11			11	23.3%	0.65 [-0.20, 1.51]	
Heterogeneity: Tau ² = 0.12; Chi ² = 1.47, df = 1 (P = 0.23); l ² = 32% Test for overall effect: 7 = 1.49 (P = 0.14)	Chi ² = 1.47, 49 (P = 0 1⁄	df = 1 (F 1)	, = 0.23)	; I² = 32%	.0			
Total [95% CL]		86	45		80	100.0%	1.01 [0.34, 1.68]	•
Heterogeneity: Tau ² = 0.75 ; Chi ² = 30.75 , df = 8 (P =	Chi ² = 30.7!	5, df = 8 (P = 0.00	0.0002); l ² = 74%	74%		+	
Test for overall effect: Z = 2.96 (P = 0.003) Test for subrroun differences: Chi2 = 1 02 df = 2 (P = 0 60) 12 = 0%	.96 (P = 0.0(.s. Chi ² = 1 ()3) 12 df = 2	(P = 0.6	0) I ² = 0	%			Favours control Favours HBOT
	= 0.0				ę			

Forest plot showing the effect of HBOT on bursting pressure (BPR) in ischemic anastomoses; HBOT – hyperbaric oxygen treatment; SD – standard deviation; IV – inverse variance, Random – random effect, CI – confidence interval; preop – preoperative; Z – Z-test; P – probability; postop – postoperative; Chi2 – chi-square test; I2 – I-square test for heterogeneity; df – degrees of freedom Figure 4

2.1.1 Preoperative HBOT Yagci (preop) ²⁸ 81.2 9 Subtotal [95% CL] Heterogeneitv: Not applicable	8D 9.2	SD Total Mean 2 10 79.3 10	Mean 79.3	. US		Total Weight 10 18.9% 10 18.9%	Mean unrerence IV, Random, [95% CL] Year 1.90 [-5.54, 9.34] 2006 1.90 [-5.54, 9.34]		IV, Random, [95% CL]
Test for overall effect: Z = 0.50 (P 2.1.2 Postoperative HBOT Hamzaoğlu ²⁸ 102.2 1 ⁴ Guzel ²² 104 15 Yagci (postop) ²⁸ 97.9 11 Adas ²⁷ 109.9 25 Subtotal [95% CL] Heterogeneity: Tau ² = 81.26; Chi ² Test for overall effect: Z = 4.90 (P	Test for overall effect: $Z = 0.50$ (P = 0.62) 2.1.2 Postoperative HBOT Hamzaoğlu ^{an} 102.2 Hamzaoğlu ^{an} 102.2 Guzel ²² 104 10 Yagci (postop) ^{2a} 97.9 17.9 10 Adas ²⁷ 109.9 25.3 10 Subtotal [95% CL] 109.9 25.3 40 Heterogeneity: Tau ² = 81.26; Chi ² = 6.76, df = Test for overall effect: Z = 4.90 (P < 0.00001)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		22.1 16.7 7.7 21.19 0.08); P	22.1 10 16.7 10 7.7 10 21.19 10 21.19 40 0.08); P = 56%	15.4% 15.7% 17.3% 62.0%	24.70 [8.21, 41.19] 34.50 [18.63, 50.37] 18.60 [6.52, 30.68] 47.90 [27.45, 68.35] 29.79 [17.87, 41.71]	1998 2006 2013 2013	↓ ↓ ↓
2.1.3 Pre and postoperative HBOT Yagci (pre+postop) ²⁸ 109 8.4 Subtotal [95% CL] Heterogeneity: Not applicable Test for overall effect: Z = 8.24 (P <	2.1.3 Pre and postoperative HBOT Yagci (pre+postop) ²⁸ 109 8.4 10 Subtotal [95% CL] Heterogeneity: Not applicable Test for overall effect: Z = 8.24 (P < 0.00001)		79.3	7.7	1	19.0% 19.0%	29.70 [22.64, 36.76] 29.70 [22.64, 36.76]	2006	÷♦
Total [95% CL] 60 100.0% Heterogeneity: Tau ² = 230.81; Chi ² = 40.73, df = 5 (P < 0.00001); l ² = 88% Test for overall effect: Z = 3.67 (P = 0.0002)	Total [95% CL] 60 Heterogeneity: Tau ² = 230.81; Chi ² = 40.73, Test for overall effect: Z = 3.67 (P = 0.0002)	Total [95% CL] 60 Heterogeneity: Tau ² = 230.81; Chi ² = 40.73, df = 5 (Test for overall effect: Z = 3.67 (P = 0.0002)	(= 5 (P ·	< 0.000	60 100.0% P < 0.00001); I ² = 88%	60 100.0% 1); I² = 88%	24.99 [11.63, 38.34]	-50 -25 Eavours co	50 -25 0 25 50 Eavours control Favours HBOT

 Figure 5

 Forest plot showing the effect of HBOT on hydroxyproline levels (HP) in ischemic anastomoses; HBOT – hyperbaric oxygen treatment; SD – standard deviation; IV – inverse variance, Random – random effect, CI – confidence interval; preop – preoperative; Z – Z-test; P – probability; postop – postoperative; Chi2 – chi-square test; I2 – I-square test for heterogeneity; df – degrees of freedom

eedom	
s of fr	
degrees	
df –	
eterogeneity;	

Std. mean difference	N, Random, [95% CL]	••			+		•			• ◆		•	-10 -5 0 5 10 Favours control Favours HBOT
ence	CL] Year] 2006 				2006	2006 			2006 		_	
Std. mean difference	m, [95%	0.65 [-0.26, 1.55] 0.65 [-0.26, 1.55]			0.61 [-0.29, 1.51]	8.43 [5.39, 11.48]	0.76 [-0.15, 1.68] 2.62 [0.11, 5.13]			1.25 [0.27, 2.22] 1.25 [0.27, 2.22]		1.57 [0.35, 2.78]	
Std. me	IV, Random, [95% CL] Year	0.65 [-0			0.61 [-C	8.43 [5.	0.76 [-(2.62 [0			1.25 [(1.25 [0		1.57 [0	
	Total Weight	22.7% 22.7%			22.7%	9.8%	22.6% 55.1%	= 92%		22.2% 22.2%		50 100.0%	= 84%
	Total	0 1			10	2	9 0 8 1	(P < 0.00001); I ² = 92%		99		50	(P < 0.0001); l² = 84%
HBOT	S	2.1				0.6	2.1	< 0.0		8.42 2.1			0.0 V 0.0
-	Mean	8.42			4.76	4.3	8.42			8.42			= 4 (P
	SD Total Mean	₽₽	16)		9	2	9 0	84, d€ (4)		99	01)	50	01) 01) 1
Control	S	0.87	(P = 0.		N	÷	1.88	ř = 23. (P = 0.	BOT	1.95	(P = 0.		P = 24. (P = 0. D=3
	Mean	9.51 0.87	pplicable Z = 1.41	НВОТ	6.04	12.1	10.01	= 4.16; Ch : Z = 2.05	berative H	11.06 1.95	pplicable : Z = 2.50		= 1.47; Ch : Z = 2.53
	Study or Subgroup	2.2.1 Preoperative HBUI Yagci (preop)22 Subtotal [95% CL]	Heterogeneity: Not applicable Test for overall effect: Z = 1.41 (P = 0.16)	2.2.2 Postoperative HBOT	Hamzaoğlu²⁰	Guzel ²²	Yagci (postop) ²² Subtotal [95% CL]	Heterogeneity: Tau ² = 4.16; Chi ² = 23.84, df = 2 Test for overall effect: Z = 2.05 (P = 0.04)	2.2.3 Pre and postoperative HBOT	Yagci (pre+postop) ²² Subtotal [95% CL]	Heterogeneity: Not applicable Test for overall effect: Z = 2.50 (P = 0.01)	Total [95% CL]	Heterogeneity: Tau ² = 1.47; Chi ² = 24.66, df = 4 (P < 0.0001); l ² = 84% Test for overall effect: Z = 2.53 (P = 0.01)

Discussion

This is the first meta-analysis describing the effect of HBOT on the outcome in colorectal surgery and shows significant improvement of BPR and HP in both normal and ischaemic anastomoses in rats after postoperative HBOT. HP is considered a reliable marker for the strength of the anastomosis and risk of AL in a rabbit model.¹⁸ Therefore, these results could be useful in the complex pathophysiology regarding HBOT and oncology in humans.

The exact mechanism of HBOT in the improvement of colorectal anastomoses is unknown. However, some steps within this pathway are becoming more clearly defined:

- HBOT reduces the risk of AL by lowering the proinflammatory response;⁹
- Elevated immune parameters like IL-1, IL-6, IL-10 and tumour necrosis factor (TNF-α) are associated with AL, indicating a connection between AL and a proinflammatory response;³²
- HBOT reduces the risk of AL by improvement of neovascularization.^{4,26,27}

Only three studies used preoperative HBOT as a part of their HBOT protocol.^{4,23,30} Of these, a significant difference was only found in the combined HBOT group of one study assessing ischaemic anastomoses,²³ but not in the other two.^{4,30} The meta-analysis for postoperative HBOT showed a stronger association between HBOT and the prevention of AL than that for preoperative HBOT. The reasons for this difference are not yet identified. Regarding the results shown in Figure 2, preoperative HBOT might possibly prevent the positive effect of postoperative HBOT.

The major limitation of the current review is the quality of the available evidence. According to the SYRCLE tool there is a risk of bias in most of the included studies. Also, the protocols varied between studies, making it problematic to combine them in a meta-analysis. Different HBOT doses (pressure and time) might influence outcome. Furthermore, the statistical heterogeneity between included studies was high, and only the meta-analysis of the subgroup using BPR as outcome measure for postoperative HBOT in non-ischaemic anastomoses could be regarded as trustworthy. The results of the other three subgroups should be interpreted with caution. Finally, most colorectal resections are performed on patients with a malignancy, whereas these studies are performed on rats without a malignancy. Although the current consensus is that HBOT does not promote cancer, further research might be needed before recommending HBOT as a routine for patients with colorectal cancer.

There is only one reported human HBOT case series of five patients who underwent an ultra-low anterior resection with a temporary loop ileostomy and who developed AL with chronic pelvic sepsis.³² All five received postoperative HBOT (90 minutes at 203–243 kPa, five days per week for

six weeks), four also receiving adjuvant chemo-radiotherapy. All the patients showed improvement in the degree of anastomotic separation and sepsis.³²

Conclusion

This meta-analysis provides some evidence to suggest HBOT may be a useful adjunct in colorectal surgery. Postoperative HBOT increases the strength of the colorectal anastomosis in rats without a malignancy, this effect appearing to be stronger in ischaemic anastomoses. To investigate the full potential of HBOT to prevent AL in human patients undergoing colorectal surgery, a pilot study should be performed. Since it would be hard to obtain the large numbers of human patients that would be necessary, further research should focus primarily on a larger systematic animal study using postoperative HBOT and with AL as the primary outcome measure.

References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. PMID: 25651787.
- 2 Clinical Practice Guidelines management of colon cancer. [cited 2017 Aug 30]. Available from: <u>https://www.fascrs.org/sites/default/files/downloads/publication/practice_parameters for the management of colon.21.pdf</u>
- 3 Clinical Practice Guidelines management of rectal cancer. [cited 2017 Aug 30]. Available from: <u>https://www.fascrs.org/sites/default/files/downloads/publication/practiceparameters for the management of rectal.2.pdf</u>.
- 4 Boersema GS, Wu Z, Kroese LF, Vennix S, Bastiaansen-Jenniskens YM, van Neck JW, et al. Hyperbaric oxygen therapy improves colorectal anastomotic healing. Int J Colorectal Dis. 2016;31:1031–8. doi: 10.1007/s00384-016-2573-y. PMID: 27041554. PMCID: PMC4834105.
- 5 Ha GW, Kim JH, Lee MR. Oncologic impact of anastomotic leakage following colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg Oncol. 2017;11:3289–99. doi: 10.1245/s10434-017-5881-8. PMID: 28608118.
- 6 Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med. 1996;334:1642–8. <u>doi: 10.1056/nejm199606203342506</u>. <u>PMID: 8628361</u>.
- 7 Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. 2017;47:24–32. doi: 10.28920/dhm47.1.24-32. PMID: 28357821.
- 8 Weaver LK, editor. Hyperbaric oxygen therapy indications, 13th ed. North Palm Beach, FL: Undersea and Hyperbaric Medical Society; 2014.
- 9 Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41:247–52. <u>PMID: 24984320</u>.
- 10 Camporesi EM. Side effects of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41:253–7. <u>PMID: 24984321</u>.
- 11 Lehm JP, Bennett MH. Predictors of middle ear barotrauma associated with hyperbaric oxygen therapy. SPUMS Journal. 2003;33:127–33.

- 12 Bosco G, Casarotto A, Nasole E, Camporesi E, Salvia R, Giovinazzo F, et al. Preconditioning with hyperbaric oxygen in pancreaticoduodenectomy: a randomized double-blind pilot study. Anticancer Res. 2014;34:2899–906. <u>PMID: 24922652</u>.
- 13 Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer a review. Target Oncol. 2012;7:233–42. <u>doi: 10.1007/s11523-012-0233-x. PMID: 23054400</u>. PMCID: PMC3510426.
- 14 Feldmeier J, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med. 2003;30:1–18. <u>PMID: 12841604</u>.
- 15 Daruwalla J, Christophi C. The effect of hyperbaric oxygen therapy on tumour growth in a mouse model of colorectal cancer liver metastases. Eur J Cancer. 2006;42:3304–11. doi: 10.1016/j.ejca.2006.08.004. PMID: 17010602.
- 16 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12. doi: 10.1016/j.jclinepi.2009.06.005. PMID: 19631508.
- 17 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. <u>doi: 10.1371/journal. pmed.1000100</u>. PMID: 19621070. PMCID: PMC2707010.
- 18 Shandall A, Lowndes R, Young HL. Colonic anastomotic healing and oxygen tension. Br J Surg. 1985;72:606–9. <u>PMID:</u> 3896373.
- 19 Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre TCC; 2014.
- 20 Hamzaoglu I, Karahasanoglu T, Aydin S, Sahin DA, Carkman S, Sariyar M, et al. The effects of hyperbaric oxygen on normal and ischemic colon anastomoses. Am J Surg. 1998;176:458–61. <u>PMID: 9874433</u>.
- 21 Erenoglu C, Uluutku H, Emeksiz S, Akin ML, Foley E, Celenk T. Effect of hyperbaric oxygen on anastomoses created under the influence of 5-FU. Undersea Hyperb Med. 2003;30:321–6. <u>PMID: 14756235</u>.
- 22 Guzel S, Sunamak O, As A, Celik V, Ferahman M, Nuri MM, et al. Effects of hyperbaric oxygen and Pgg-glucan on ischemic colon anastomosis. World J Gastroenterol. 2006;12:1421–5. <u>PMID: 16552813</u>.
- 23 Yagci G, Ozturk E, Ozgurtas T, Gorgulu S, Kutlu OC, Topal T, et al. Preoperative and postoperative administration of hyperbaric oxygen improves biochemical and mechanical parameters on ischemic and normal colonic anastomoses. J Invest Surg. 2006;19:237–44. doi: 10.1080/08941930600778230. PMID: 16835138.
- 24 Sucullu I, Sinan H, Filiz AI, Yildiz S, Yucel E, Kurt Y, et al. The effects of hyperbaric oxygen therapy on colonic anastomosis in rats with peritonitis. J Invest Surg. 2008;21:195–200. doi: 10.1080/08941930802155534. PMID: 18615316.
- 25 Azevedo LA, Parra RS, Da Rocha JJ, Ramalho LN, Ramalho FS, Feres O. Hyperbaric oxygen on the healing of ischemic colonic anastomosis an experimental study in rats. Undersea Hyperb Med. 2010;37:405–11. PMID: 21226391.
- 26 Rocha AA, Leal RF, Ayrizono Mde L, Chung WF, Coy CS, Lee HD, et al. Hyperbaric oxygen therapy and mechanical resistence of the colonics anastomosis in rats with peritonitis. Acta Cir Bras. 2010;25:368–74. <u>PMID: 20676497</u>.
- 27 Adas M, Kemik O, Adas G, Arikan S, Kuntsal L, Kapran Y, et al. Is combined therapy more effective than growth hormone or hyperbaric oxygen alone in the healing of left ischemic and non-ischemic colonic anastomoses? Clinics (Sao Paulo).

2013;68:1440-5. doi: 10.6061/clinics/2013(11)10. PMID: 24270957. PMCID: PMC3812562.

- 28 Kemik O, Adas G, Arikan S, Gurluler E, Dogan Y, Toklu AS, et al. Evaluation of the effects of hyperbaric oxygen treatment and enoxaparin on left colon anastomosis. An experimental study. Eur Rev Med Pharmacol Sci. 2013;17:2286–92. <u>PMID</u>: 24065219.
- 29 Yildiz R, Can MF, Yagci G, Ozgurtas T, Guden M, Gamsizkan M, et al. The effects of hyperbaric oxygen therapy on experimental colon anastomosis after preoperative chemoradiotherapy. Int Surg. 2013;98:33–42. doi: 10.9738/ CC130.2. PMID: 23438274. PMCID: PMC3723167.
- 30 Poyrazoglu Y, Topal T, Yuksel R, Bircan FS, Simsek K, Gocgeldi E, et al. Effects of hyperbaric oxygen and preconditioning on wound healing in colonic anastomoses. J Invest Surg. 2015;28:188–95. doi: 10.3109/08941939.2014.999961. PMID: 26086171.
- 31 Emir S, Gurdal SO, Sozen S, Bali I, Yesildag E, Celik A, et al. Does hyperbaric oxygen therapy reduce the effects of ischemia on colonic anastomosis in laparoscopic colon resection? Ann Ital Chir. 2016;87:83–91. <u>PMID: 27026260</u>.
- 32 Komen N, de Bruin RW, Kleinrensink GJ, Jeekel J, Lange JF. Anastomotic leakage, the search for a reliable biomarker. A review of the literature. Colorectal Dis. 2008;10:109–15; discussion 15–7. doi: 10.1111/j.1463-1318.2007.01430.x. PMID: 18199290.

Acknowledgements

We thank Professor H Putter, Department of Medical Statistics and Bioinformatics, for statistical support, and CAM van der Hoorn, Walaeus Library, both of the Leiden University Medical Centre, Leiden, The Netherlands and OC Lindner, Library, Alrijne Hospital, Leiderdorp, The Netherlands for their help with the literature search.

Conflicts of interest and funding: nil

Submitted: 28 March 2018; revised 12 June, 30 July and 15 August 2018

Accepted: 16 August 2018

Copyright: This article is the copyright of the authors who grant *Diving and Hyperbaric Medicine* a non-exclusive licence to publish the article in electronic and other forms.